Recruiting
Epstein-Barr virus infection reactivation+3
RecruitingStudy on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection
Registered drug
Study on the Effectiveness of 2LEBV and 2LXFS for Reducing Fatigue in Patients with Epstein-Barr Virus Infection
Registered drug
- Disease:Epstein-Barr virus infection reactivationEpstein-Barr virus infection+2
- Substances:Interferon AlfaInterferon Gamma+12
Countries:
Belgium
Belgium- Participants:0–17 years · 18–64 years
- Substances:Interferon Alfa
